Published in Blood Rev on June 01, 1997
Human T-lymphotropic virus type 1 p30(II) functions as a transcription factor and differentially modulates CREB-responsive promoters. J Virol (2000) 1.31
Critical role of human T-lymphotropic virus type 1 accessory proteins in viral replication and pathogenesis. Microbiol Mol Biol Rev (2002) 1.20
Endoplasmic reticulum and cis-Golgi localization of human T-lymphotropic virus type 1 p12(I): association with calreticulin and calnexin. J Virol (2001) 1.18
The human T-cell leukemia virus Rex protein. Front Biosci (2005) 1.14
Prevalence of antibody to human T cell leukaemia/lymphoma virus in women attending antenatal clinic in southeast London: retrospective study. BMJ (2000) 1.12
Phosphorylation regulates human T-cell leukemia virus type 1 Rex function. Retrovirology (2009) 0.83
Detection of human T-lymphotropic virus (HTLV) tax sequences in New York City blood donors seronegative for HTLV types 1 and 2. Clin Diagn Lab Immunol (2003) 0.81
Infection of female primary lower genital tract epithelial cells after natural pseudotyping of HIV-1: possible implications for sexual transmission of HIV-1. PLoS One (2014) 0.78
Seroprevalence of human T-cell lymphoma/leukemia virus type-1 (HTLV-1) antibodies among blood donors at Enugu, Nigeria. J Blood Med (2015) 0.77
The human immunodeficiency virus type 1 vpr gene arrests infected T cells in the G2 + M phase of the cell cycle. J Virol (1995) 4.42
High rate of HTLV-II infection in seropositive i.v. drug abusers in New Orleans. Science (1989) 3.00
Analysis of rev gene function on human immunodeficiency virus type 1 replication in lymphoid cells by using a quantitative polymerase chain reaction method. J Virol (1989) 2.67
Identification of the gene responsible for human T-cell leukaemia virus transcriptional regulation. Nature (1986) 2.49
Requirement of human immunodeficiency virus type 1 nef for in vivo replication and pathogenicity. J Virol (1994) 2.45
The x gene is essential for HTLV replication. Science (1985) 2.44
Genetic analysis of human immunodeficiency virus type 1 integrase and the U3 att site: unusual phenotype of mutants in the zinc finger-like domain. J Virol (1995) 2.22
Genetic and biological comparisons of pathogenic and nonpathogenic molecular clones of simian immunodeficiency virus (SIVmac). AIDS Res Hum Retroviruses (1992) 1.92
Immune response of rhesus macaques to recombinant simian immunodeficiency virus gp130 does not protect from challenge infection. J Virol (1993) 1.68
A second isolate of HTLV-II associated with atypical hairy-cell leukemia. N Engl J Med (1986) 1.44
Detection and cloning of new HTLV-related endogenous sequences in man. Nucleic Acids Res (1989) 1.36
Modeling human lymphoid precursor cell gene therapy in the SCID-hu mouse. Blood (1994) 1.33
Apoptosis in AIDS. Apoptosis (2001) 1.31
Patterns of repair of dystrophic mouse muscle: studies on isolated fibers. Dev Dyn (1999) 1.29
Coreceptor utilization by human immunodeficiency virus type 1 is not a primary determinant of neutralization sensitivity. J Virol (1998) 1.28
Activation of the GM-CSF promoter by HTLV-I and -II tax proteins. Oncogene (1989) 1.22
Aging normal and dystrophic mouse muscle: analysis of myogenicity in cultures of living single fibers. Muscle Nerve (1998) 1.21
Comparison of cell cycle arrest, transactivation, and apoptosis induced by the simian immunodeficiency virus SIVagm and human immunodeficiency virus type 1 vpr genes. J Virol (2001) 1.21
ATR and GADD45alpha mediate HIV-1 Vpr-induced apoptosis. Cell Death Differ (2005) 1.19
Lentivirus vectors using human and simian immunodeficiency virus elements. J Virol (1999) 1.15
Relative prevalence and risk factors of HTLV-I and HTLV-II infection in US blood donors. Lancet (1991) 1.12
Primary isolate neutralization by HIV type 1-infected patient sera in the era of highly active antiretroviral therapy. AIDS Res Hum Retroviruses (1999) 1.12
A histochemical method for the simultaneous demonstration of capillaries and fiber type in skeletal muscle. Stain Technol (1987) 1.07
Establishment of human T-cell leukemia virus type I T-cell lymphomas in severe combined immunodeficient mice. Blood (1993) 1.06
CD26 antigen and HIV fusion? Science (1994) 1.05
Regulation of HTLV-II gene expression by Rex involves positive and negative cis-acting elements in the 5'long terminal repeat. Virology (1991) 1.04
Polypyrimidine tract-binding protein and heterogeneous nuclear ribonucleoprotein A1 bind to human T-cell leukemia virus type 2 RNA regulatory elements. J Virol (1995) 1.03
In vitro mutagenesis of the human T-cell leukemia virus types I and II tax genes. J Virol (1989) 1.03
Defective lentiviral vectors are efficiently trafficked by HIV-1 and inhibit its replication. Mol Ther (2001) 1.03
Human T-cell leukemia virus type II Rex binding and activity require an intact splice donor site and a specific RNA secondary structure. J Virol (1991) 1.03
Specific binding of polypyrimidine tract binding protein and hnRNP A1 to HIV-1 CRS elements. Virus Genes (1996) 1.02
Upregulation of survivin by HIV-1 Vpr. Apoptosis (2003) 1.02
Roles of p53 and caspases in the induction of cell cycle arrest and apoptosis by HIV-1 vpr. Exp Cell Res (1999) 0.99
Mutation of the methylated tRNA(Lys)(3) residue A58 disrupts reverse transcription and inhibits replication of human immunodeficiency virus type 1. J Virol (2001) 0.97
Multigene lentiviral vectors based on differential splicing and translational control. Mol Ther (2001) 0.96
Inhibition of HIV-1 replication using a mutated tRNALys-3 primer. J Biol Chem (1997) 0.95
In vivo properties of three human HER2/neu-expressing murine cell lines in immunocompetent mice. Lab Anim Sci (1999) 0.95
Ectopic skeletal muscles derived from myoblasts implanted under the skin. J Cell Sci (1998) 0.94
Viral gene delivery to skeletal muscle: insights on maturation-dependent loss of fiber infectivity for adenovirus and herpes simplex type 1 viral vectors. Hum Gene Ther (1997) 0.94
HTLV-I and HTLV-II tax trans-activate the human EGR-1 promoter through different cis-acting sequences. Oncogene (1992) 0.91
Human T-cell leukemia virus type 2 Rex inhibits pre-mRNA splicing in vitro at an early stage of spliceosome formation. J Virol (1996) 0.89
Detection of mutated K12-ras in histologically negative lymph nodes as an indicator of poor prognosis in stage II colorectal cancer. Clin Colorectal Cancer (2001) 0.89
HTLV type 1 Tax transduction in microglial cells and astrocytes by lentiviral vectors. AIDS Res Hum Retroviruses (2000) 0.89
A phase I trial of immunotherapy with intratumoral adenovirus-interferon-gamma (TG1041) in patients with malignant melanoma. Cancer Gene Ther (2003) 0.87
Inhibition of HIV type 1 infection with a RANTES-IgG3 fusion protein. AIDS Res Hum Retroviruses (1998) 0.87
Hypercalcemia, parathyroid hormone-related protein expression and human T-cell leukemia virus infection. Leuk Lymphoma (1994) 0.87
[Epidemiology and burden of acute otitis media in Valencia (Spain)]. An Pediatr (Barc) (2004) 0.86
Slow axonal regrowth but extreme hyperinnervation of target muscle after suture of the facial nerve in aged rats. Neurobiol Aging (1998) 0.86
A phase I trial of autologous CD34+ hematopoietic progenitor cells transduced with an anti-HIV ribozyme. Hum Gene Ther (1999) 0.85
Characterization of group specific antibodies in primates: studies with SIV envelope in macaques. J Med Primatol (1992) 0.85
Adult T-cell lymphoma in Israeli patients of Iranian origin. Cancer (1990) 0.85
Efficient gene transfer into human monocyte-derived macrophages using defective lentiviral vectors. Cell Mol Biol (Noisy-le-grand) (2003) 0.84
Lentiviral vectors and gene therapy. Front Biosci (1999) 0.84
Eradication of pre-established lymphoma using herpes simplex virus amplicon vectors. Blood (1999) 0.83
A colony assay for in vitro transformation by human T cell leukemia viruses type I and type II. Blood (1987) 0.82
Binding of nuclear proteins to HTLV-II cis-acting repressive sequence (CRS) RNA correlates with CRS function. Virology (1994) 0.81
Cell type-specific activity of the N-myc promoter in human neuroblastoma cells is mediated by a downstream silencer. Oncogene (1995) 0.81
A B7.1-antibody fusion protein retains antibody specificity and ability to activate via the T cell costimulatory pathway. J Immunol (1998) 0.81
Characterization of rhesus macaque B-lymphoblastoid cell lines infected with simian type D retrovirus. AIDS Res Hum Retroviruses (1991) 0.80
The rheumatoid factor reactivity of a human IgG monoclonal autoantibody is encoded by a variant V kappa II L chain gene. J Immunol (1991) 0.80
Effects of the farnesyl transferase inhibitor R115777 on normal and leukemic hematopoiesis. Leukemia (2003) 0.80
Development of herpes simplex virus-1 amplicon-based immunotherapy for chronic lymphocytic leukemia. Blood (2001) 0.79
Effects of megakaryocyte growth and development factor on survival and retroviral transduction of T lymphoid progenitor cells. Hum Gene Ther (1998) 0.79
Cell type-specific expression and negative regulation by retinoic acid of the human N-myc promoter in neuroblastoma cells. Oncogene (1992) 0.79
2-Chlorodeoxyadenosine to treat refractory histiocytosis X. N Engl J Med (1993) 0.79
A murine B cell lymphoma expressing human HER2 / neu undergoes spontaneous tumor regression and elicits antitumor immunity. Cancer Immunol Immunother (2001) 0.78
Forced MyHCIIB expression following targeted genetic manipulation of conditionally immortalized muscle precursor cells. Exp Cell Res (1999) 0.77
Development of an Rev-independent, minimal simian immunodeficiency virus-derived vector system. Hum Gene Ther (2001) 0.77
The effect of intraoperative ischemia on the recovery of contractile function after free muscle transfer. J Hand Surg Am (1988) 0.77
Selection and use of ligands for receptor-mediated gene delivery to myogenic cells. Gene Ther (1997) 0.77
Immunopathogenesis of HIV and HTLV-1 infection: mechanisms for lymphomagenesis. Cancer Treat Res (2001) 0.76
A patient with progressive myelopathy and antibodies to human T-cell leukemia virus type I and human immunodeficiency virus type 1 in serum and cerebrospinal fluid. Arch Neurol (1990) 0.76
Induction of cell-cycle arrest in cervical cancer cells by the human immunodeficiency virus type 1 viral protein R. Obstet Gynecol (2000) 0.76
A RANTES-antibody fusion protein retains antigen specificity and chemokine function. J Immunol (1998) 0.76
Brentuximab vedotin does not cause clinically relevant QTc interval prolongation in patients with CD30-positive hematologic malignancies. Cancer Chemother Pharmacol (2013) 0.75
A comparative histochemical and morphometric study of canine skeletal muscle. Can J Vet Res (1989) 0.75
Lentivirus and foamy virus vectors: novel gene therapy tools. Expert Opin Biol Ther (2001) 0.75
Sequence analysis of the new human T cell leukemia/lymphoma virus type I isolate (HTLV-I) in Israel. Isr J Med Sci (1994) 0.75
Negative regulation of gene expression from the HTLV type II long terminal repeat by Rex: functional and structural dissociation from positive posttranscriptional regulation. AIDS Res Hum Retroviruses (1996) 0.75
A Phase I study of human gamma interferon gene-transduced tumor cells in patients with neuroblastoma. Hum Gene Ther (1998) 0.75
Fiber type morphometry and capillary geometry in free, vascularized muscle transfers. Microsurgery (1991) 0.75
SIV and FIV vaccine studies at UC Davis: 1991 update. AIDS Res Hum Retroviruses (1992) 0.75
Elevated serum interleukin-2 receptors in a newly identified group with high rates of human T cell leukemia virus type I infection in Israel. J Infect Dis (1991) 0.75
The role of the x gene in HTLV associated malignancy. Cancer Surv (1986) 0.75
Parathyroid hormone-related protein gene expression and human T cell leukemia virus-1 infection. Miner Electrolyte Metab (1995) 0.75
Detection of human T-cell leukemia/lymphoma virus type I in a transfusion recipient with chronic myelopathy. Neurology (1989) 0.75
CD-20 expression in post-transplant lymphoproliferative disorders: treatment with rituximab. Am J Hematol (2000) 0.75
Skeletal muscle fiber type, fiber size, and capillary supply in elite soccer players. Int J Sports Med (1990) 0.75
Molecular characterization of HTLV-I infection in Israel. Ann N Y Acad Sci (1994) 0.75